Barbara Savoldo

Abstract Almost 1 million people in the United States suffer from multiple sclerosis (MS). Current therapies suppress protective immunity and are non-curative. Antigen-specific therapies can selectively suppress autoreactive cells, preserving protective immunity. B cell dysregulation, a major driver of MS, remains largely untargeted for antigen-specific tolerance. We hypothesize that targeting B cells with antigen-loaded microparticles will enhance therapeutic efficacy.

100th Anniversary Viewpoint Open Access | 10.1172/JCI177160 Published in Volume 134, Issue 2 on January 16, 2024 J Clin Invest. 2024;134(2):e177160. https://doi.org/10.1172/JCI177160. © 2024 Savoldo et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

H&OWhat prompted your research of chimeric antigen receptor (CAR) T-cell therapy in Hodgkin lymphoma? BSIt has been known for a long time that Hodgkin lymphoma is susceptible to T-cell immune-mediated treatment. As researchers at Baylor College of Medicine, my colleagues and I evaluated the possibility of using T cells to target the Epstein-Barr virus, which is expressed in approximately 40% of patients with Hodgkin lymphoma.